Cargando…
Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in significantly improved anti-tumor activity in vitro and in vivo
Lysosomal cysteine peptidase cathepsin B, involved in multiple processes associated with tumor progression, is validated as a target for anti-cancer therapy. Nitroxoline, a known antimicrobial agent, is a potent and selective inhibitor of cathepsin B, hence reducing tumor progression in vitro and in...
Autores principales: | Mitrović, Ana, Sosič, Izidor, Kos, Špela, Tratar, Urša Lampreht, Breznik, Barbara, Kranjc, Simona, Mirković, Bojana, Gobec, Stanislav, Lah, Tamara, Serša, Gregor, Kos, Janko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601720/ https://www.ncbi.nlm.nih.gov/pubmed/28938624 http://dx.doi.org/10.18632/oncotarget.19296 |
Ejemplares similares
-
Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity
por: Mirković, Bojana, et al.
Publicado: (2015) -
Organoruthenated Nitroxoline Derivatives Impair Tumor
Cell Invasion through Inhibition of Cathepsin B Activity
por: Mitrović, Ana, et al.
Publicado: (2019) -
Redox-Based Inactivation of Cysteine Cathepsins by Compounds Containing the 4-Aminophenol Moiety
por: Mirković, Bojana, et al.
Publicado: (2011) -
Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection
por: Milan Bonotto, Rafaela, et al.
Publicado: (2023) -
Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma
por: Kos, Spela, et al.
Publicado: (2019)